Who are Placebo+ Fluorouracil+Cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 5-fluorouracil/oxaliplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-fluorouracil-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo+ Fluorouracil+Cisplatin — Competitive Intelligence Brief

Placebo+ Fluorouracil+Cisplatin (Placebo+ Fluorouracil+Cisplatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (antimetabolite + platinum agent). Area: Oncology.

phase 3 Chemotherapy combination (antimetabolite + platinum agent) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo+ Fluorouracil+Cisplatin (Placebo+ Fluorouracil+Cisplatin) — CStone Pharmaceuticals. This combination uses fluorouracil and cisplatin chemotherapy agents to inhibit DNA synthesis and induce cancer cell death, with placebo as a control arm in the trial design.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo+ Fluorouracil+Cisplatin TARGET	Placebo+ Fluorouracil+Cisplatin	CStone Pharmaceuticals	phase 3	Chemotherapy combination (antimetabolite + platinum agent)
5-fluorouracil/oxaliplatin	5-fluorouracil/oxaliplatin	Seoul National University Hospital	phase 3	Chemotherapy combination (antimetabolite + platinum agent)	Thymidylate synthase (5-FU); DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (antimetabolite + platinum agent) class)

CStone Pharmaceuticals · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo+ Fluorouracil+Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-fluorouracil-cisplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab